Dr. Francisco Bengoa
EN
Back to the wiki

Bone tumors

Bone plasmacytoma

BoneMalignant hematologic neoplasm — not a sarcomaHaematopoietic neoplasms of bone

Epidemiology

A malignant blood (hematologic) cancer of plasma cells — not a sarcoma — that can appear as a solitary bone lesion, especially in adults. The workup does not end with the bone lesion: multiple myeloma must be sought with laboratory tests, bone marrow, and whole-body imaging.

Basic features

It causes pain, a lytic (bone-thinning) lesion, or a fracture, and it always requires ruling out multiple myeloma with blood, urine, and imaging studies directed by hematology.

Usual treatment

Hematology directs the systemic evaluation and the treatment plan (often local radiotherapy to the solitary lesion). The role of orthopedic surgery is limited to a planned biopsy, mechanical stability, and management of fractures.

Outcomes and prognosis

Long-term hematology follow-up is key, because a portion of solitary plasmacytomas progresses to multiple myeloma over time. The prognosis depends on that progression, on the stage, and on the response to systemic treatment — not on the appearance of the bone lesion.

Warning signs

These signs do not necessarily mean cancer, but they warrant evaluation before operating on or needling a mass.

  • A soft-tissue mass that grows, is larger than 5 cm, or is deep.
  • Persistent, night-time or progressive bone pain, especially if it limits activity.
  • A fracture from minimal trauma, or an aggressive bone lesion on an X-ray.
  • A lump that comes back after previous surgery.
  • Neurological symptoms, rapid swelling, or pain associated with a mass.

This information is general and does not replace a medical evaluation. A musculoskeletal tumor must be interpreted together with imaging, physical examination, biopsy when appropriate and each patient's context.

Specialist evaluation

If you have a mass, a bone lesion or a report suggesting a tumor, book an evaluation.

Book an appointment